Last updated: February 17, 2026
Summary
NDC 00054-0235 corresponds to a biologic drug primarily used for the treatment of inflammatory conditions, such as Crohn's disease and ulcerative colitis. The drug's market landscape involves intense competition from biosimilars and other biologics. Price projections indicate moderate reductions driven by biosimilar entry, while the drug's revenue sustains due to patent protections and established prescribing patterns.
What is the current market landscape for NDC 00054-0235?
Market Overview
NDC 00054-0235, marketed under the name "Remicade" (infliximab), is a monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α). As of 2023, infliximab maintains a significant share in the biologics segment for autoimmune diseases.
Key points:
- Market Size: The global TNF inhibitor market was valued at approximately $30 billion in 2022 and is projected to reach $37 billion by 2027 with compound annual growth rate (CAGR) of 4%.
- Sales: Infliximab alone generated revenues around $8 billion in 2022, with key markets in the U.S., Europe, and Japan.
- Competitive Landscape: The segment includes biosimilars such as CT-P13 (Remsima, Inflectra), launched in Europe in 2015 and expanded globally in subsequent years. Major competitors include adalimumab (Humira) and newer agents like golimumab and certolizumab pegol.
Regulatory and Patent Context
- Patent Status: The primary patents for Remicade expired in the U.S. in 2018, opening the market for biosimilar competition. Some secondary patents extend protections until 2023-2025, depending on jurisdiction.
- Biosimilars: Multiple biosimilars received approval in different regions, accelerating generic-like competition and pressuring prices.
What are the current pricing trends for NDC 00054-0235?
List Price and Reimbursement Trends
- List Prices: The wholesale acquisition cost (WAC) for Remicade was approximately $2,600 per 100 mg dose in 2023, with treatment regimens typically requiring multiple doses.
- Net Prices: Due to discounts, rebates, and market negotiations, actual reimbursement rates are roughly 30-50% below list prices in the U.S., often resulting in effective prices around $1,300 to $2,000 per 100 mg dose.
- Biosimilar Pricing: Biosimilars launched in multiple countries are priced 15-30% lower than the originator, further reducing market prices and expanding access.
| Year |
Remicade (USD per dose) |
Biosimilars (USD per dose) |
Market share of biosimilars |
| 2022 |
~$2,600 |
~$2,200 |
20% in the U.S., 40% in Europe |
| 2023 |
~$2,500 |
~$1,950 |
~35% in the U.S., 50% in Europe |
Price Drivers
- Competition from biosimilars
- Negotiations with payers
- Policy shifts favoring biosimilar substitution
- Manufacturer discounts and rebate structures
What are the price projection estimates for the next five years?
Projection Assumptions
Projection models incorporate biosimilar penetration, payer negotiations, and potential policy changes. The key assumptions include:
- Incremental biosimilar uptake accelerates to capture 50% of the market by 2025 in the U.S.
- Price erosion stabilizes at 20-25% relative to current levels over 2024-2027.
- No significant regulatory or patent extensions delay biosimilar entry or price stabilization.
Price Projections 2024–2028
| Year |
Average Price per 100 mg Dose (USD) |
Market Share of Biosimilars |
Revenue Implications |
| 2024 |
~$2,350 |
45% |
10-15% revenue decline in U.S. |
| 2025 |
~$2,200 |
50% |
Stabilization at lower price point |
| 2026 |
~$2,150 |
55% |
Market saturation limits further price cuts |
| 2027 |
~$2,100 |
60% |
Revenue stabilizes with volume-driven shifts |
Key Influencing Factors
- Biosimilar market share increases
- Payer incentives for substitution
- Potential cost-saving measures by healthcare systems
- Patent litigation outcomes
What is the outlook for revenue and market share?
Revenue Projections
The revenue for NDC 00054-0235 is expected to decline gradually as biosimilars gain market share. In the U.S., revenues from infliximab could decrease from approximately $3.5 billion in 2023 to around $2.8 billion by 2025, assuming a 20-25% price reduction and 50% biosimilar penetration.
Globally, revenue declines may be less pronounced due to slower biosimilar adoption in certain regions like Japan and Canada.
Market Share Trends
- Biosimilar share expected to reach near 50% in the U.S. by 2025.
- Original biologic retains a significant share in Europe, where pricing and patent protections persist longer than in the U.S.
- Demand continues in underserved regions and for certain formulary preferences.
What are the strategic considerations for stakeholders?
- Manufacturers of originator biologics need to adapt to a lower-price environment with emphasis on differentiation through formulation, delivery devices, or patient support programs.
- Biosimilar companies should focus on expanding access and reducing prices further to increase adoption.
- Payers and policymakers aim to contain costs, favoring early biosimilar switching and innovative contracting arrangements.
Key Takeaways
- NDC 00054-0235 (Remicade) faces a mature market with evolving biosimilar competition.
- Prices are declining due to biosimilar entry, with upward pressure on volume.
- Price erosion is projected at 20-25% over the next few years, stabilizing by 2026.
- Revenue declines will depend on biosimilar adoption rates, especially in the U.S.
- Strategic responses centered on differentiation and cost management are critical for manufacturers and payers.
FAQs
1. How much can prices of infliximab drop with biosimilar competition?
Prices tend to fall 15-30% relative to the originator, with further reductions possible as biosimilar market share increases.
2. Which regions are most likely to see the fastest biosimilar adoption?
Europe and certain Asian markets adopt biosimilars rapidly due to aggressive pricing policies and regulatory support. The U.S. lags slightly due to patent litigation and reimbursement complexities.
3. Will patent extensions affect pricing and market share?
Yes. Patent litigation can delay biosimilar entry, maintaining higher prices longer. Conversely, patent expirations typically accelerate biosimilar adoption.
4. How do payers influence the retail price of the drug?
Payers negotiate rebates and implement formulary preferences, which ultimately reduce net prices paid by insurers and providers.
5. Are there opportunities for new revenue streams for original biologic manufacturers?
Yes. Innovations in delivery, formulation, or combination therapies can offset revenue declines from biosimilar competition.
Citations
[1] Evaluate Pharma, "Biologics Market Data," 2022.
[2] IQVIA, "Global Market Reports," 2023.
[3] U.S. FDA, "Biosimilar Approval Summary," 2022.
